UNSPSC 51313201: Piprinhydrinate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23NO.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SI78RFJ7XI, chemically known as theophylline, 8-chloro-, compd. with 4-(diphenylmethoxy)-1-methylpiperidine (1:1) but generally known as piprinhydrinate, which bears US NIH Compound Identifier 71640. European Medicines Agency schedules Piprinhydrinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09886MIG.

UNSPSC 51313201 Piprinhydrinate is a Commodity code that in recent state and local procurement reflects a much broader scope than the code name suggests: state and local governments are soliciting pharmaceuticals, over-the-counter products, naloxone, drug deactivation systems, and direct-to-manufacturer prescription programs under this classification. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Recent solicitations show demand across community health initiatives, pharmacy benefit programs, and bulk pharmaceutical distribution networks serving state and local facilities.

Activity is concentrated in Florida, Texas, and Minnesota based on recent postings. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration, through MMCAP, released RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products for distribution across state and local government facilities, with proposals due March 26, 2026; this RFP requires FDA compliance, cGMP certification, DSCSA compliance, and pricing through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with a 75 percent evaluation weighting on price competitiveness and a 3 percent administrative fee on all purchases.